Key statistics
As of last trade, Terns Pharmaceuticals Inc (430:DUS) traded at 5.55, 64.69% above the 52 week low of 3.37 set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.45 |
---|---|
High | 5.55 |
Low | 5.45 |
Bid | 5.45 |
Offer | 5.65 |
Previous close | 5.55 |
Average volume | 241.67 |
---|---|
Shares outstanding | 84.94m |
Free float | 84.82m |
P/E (TTM) | -- |
Market cap | 491.80m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 15:00 GMT.
More ▼
Announcements
- Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
- Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Terns Announces Pricing of Upsized $150.15 Million Public Offering
- Terns Announces Proposed Public Offering
- Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
- Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
More ▼